SEVELAMER HYDROCHLORIDE ![]() (se-vel'a-mer) ![]() Renagel Classifications: electrolyte and water balance agent; phosphate binder; Therapeutic: phosphate binder Pregnancy Category: C |
403 mg capsules; 400 mg, 800 mg tablets
Polymer that binds intestinal phosphate; interacts with phosphate by way of ion-exchange and hydrogen binding. Advantageously, does not contain aluminum or calcium in treating hyperphosphatemia in end stage kidney failure.
Indicated by a serum phosphate level ≤6.0 mg/dL.
Reduction of serum phosphorus in patients with end-stage kidney disease.
Hypophosphatemia; hypersensitivity to sevelamer HCl; fecal impaction; bowel obstruction; hypophosphatemia; appendicitis; dysphagia, GI bleeding, major GI surgery; pregnancy (category C), lactation. Safety and efficacy in children <18 y are not established.
GI motility disorders; vitamin deficiencies (especially vitamins D, E, and K and folic acid).
Hyperphosphatemia Adult: PO 2 capsules or tablets t.i.d. for serum phosphorus >6 and <7.5 mg/dL; 3 capsules or tablets t.i.d. for serum phosphorus >7.5 and <9 mg/dL; 4 capsules or tablets t.i.d. for serum phosphorus ≥9 mg/dL |
Assessment & Drug Effects
Patient & Family Education